Tocqueville Asset Management L.P. Jounce Therapeutics, Inc. Transaction History

Tocqueville Asset Management L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$6.5 - $8.37 $139,425 - $179,536	-21,450 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$7.27 - $21.88 $156,305 - $470,420	-21,500 Reduced 50.06%	21,450 $164,000
Q4 2017 Feb 13, 2018	BUY	$12.52 - $17.82 $537,734 - $765,369	42,950	42,950 $548,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.